Grifols in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Emphysema

 

• Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin^®-C (Alpha1-Proteinase Inhibitor [Human]) to slow emphysema progression in patients with alpha-1-antitrypsin (AAT) deficiency (known as alpha-1)
• Alpha-1 is the most common genetic risk factor for chronic obstructive pulmonary disease (COPD), a group of respiratory diseases that includes emphysema. COPD is the third leading cause of death worldwide¹
• Grifols’ advances in the science of alpha-1 underscore its robust innovation pipeline and commitment to testing and treatment for the alpha-1 community

https://www.biospace.com/article/releases/grifols-meets-enrollment-target-in-phase-3-study-of-two-dose-regimens-of-prolastin-c-in-patients-with-emphysema-due-to-alpha-1-antitrypsin-deficiency/